Opinion|Videos|April 18, 2025
Benefits of Nonsteroidal Topical JAK Inhibitors for Moderate Pediatric Atopic Dermatitis
Author(s)James Song, MD, FAAD
James Song, MD, FAAD, discusses how topical Janus kinase inhibitors offer distinct advantages for children with moderate atopic dermatitis by providing effective inflammation control without the adverse effects of topical corticosteroids, particularly in sensitive areas like the face and intertriginous regions.
Advertisement
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following:
- For children with moderate disease who may not yet require systemic therapy (or who aren’t eligible), what advantages would a nonsteroidal, topical Janus kinase inhibitor offer over current options?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
Expert Panel Unanimously Backs DecisionDx-Melanoma for Guiding Personalized Cancer Care
4
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
5